Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...
The new oral therapy demonstrates superior lesion healing for complex patients who have few current treatment options.
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
The incidence of neonatal herpes simplex virus (HSV) infections in the UK and Ireland increased dramatically over 15 years, and outcomes remained poor, with mortality and long-term neurologic ...
A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
Researchers at the University of Jyväskylä (Finland), in cooperation with national and international research groups, have ...
Herpes is one of the most common viral infections in the world, yet it remains widely misunderstood. Caused by the herpes ...
– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...
Inhibiting the herpes simplex virus type 1 viral enzyme uracil-DNA glycosylase reactivates the natural defense protein apolipoprotein B mRNA editing enzyme, catalytic polypeptide-1 (APOBEC1) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results